[ARS] Immunovant, Inc. SEC Filing

Filing Impact

(No impact)

Filing Sentiment

(Neutral)

Form Type

ARS

Rhea-AI Filing Summary

07/09/2025 - 04:57 PM

ARS - Immunovant, Inc.

ARS Filing - Immunovant, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Immunovant, Inc. (IMVT)

Acceptance Date: 2025-07-09T16:57:33.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Immunovant Inc

NASDAQ:IMVT

IMVT Rankings

#2235 Ranked by Market Cap

N/A Ranked by Dividends

IMVT Latest News

May 29, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Apr 21, 2025

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Feb 6, 2025

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

IMVT Latest SEC Filings

Jul 11, 2025

[Form 4] Immunovant, Inc. Insider Trading Activity

Jul 11, 2025

[Form 4] Immunovant, Inc. Insider Trading Activity

Jul 9, 2025

[DEFA14A] Immunovant, Inc. Additional Proxy Soliciting Materials

Jul 9, 2025

[DEF 14A] Immunovant, Inc. Definitive Proxy Statement

Jun 25, 2025

[144] Immunovant, Inc. SEC Filing

IMVT Stock Data

Market Cap 2.89B

Float 68.40M

Insiders Ownership 58.08%

Institutions Ownership 47.58%

Short Percent 9.06%

Industry Biotechnology

Sector Biological Products, (no Disgnostic Substances)

Website Link

Country United States

City NEW YORK